β-Amyloid 1-42 (Aβ1-42) (CLIA)
Product Detail
Product Description
The Vazyme β-Amyloid 1-42 (Aβ1-42) CLIA Assay is designed for quantitative measurement of Aβ1-42 in research samples for Alzheimer’s disease biomarker studies. It supports automated chemiluminescence immunoassay workflows on compatible analyzers.
This Aβ1-42 immunoassay uses a double-antibody sandwich format. Monoclonal anti-Aβ1-42 antibodies coated onto magnetic particles serve as capture antibodies, while acridinium ester-labeled monoclonal anti-Aβ1-42 antibodies function as detection antibodies. The relative light units (RLUs) measured are directly proportional to the Aβ1-42 concentration in the sample.
Features
Automated CLIA Workflow. Compatible with automated chemiluminescence immunoassay analyzers for streamlined Aβ1-42 quantification in research workflows.
Proprietary High-affinity Antibodies. In-house developed monoclonal anti-Aβ1-42 antibodies enable sensitive and specific detection.
Defined Analytical Performance. Limit of Blank (LoB) ≤0.50 pg/mL; linear range 1.00–100.00 pg/mL with correlation coefficient r ≥0.9900.
Precision and Trueness Specifications. Repeatability CV ≤8.00%, intermediate precision CV ≤15.00%, and trueness within −15% to +15%.
Specification
| Specification | Performance |
|---|---|
| Product name | β-Amyloid 1-42 (Aβ1-42) CLIA Assay |
| Catalog number | AD008 |
| Pack size | 100 tests/kit |
| Principle | Double-antibody sandwich chemiluminescence immunoassay (CLIA) |
| Species Reactivity (Validated) | human, 5xFAD mice, Non-human primate, pig, brain organoids |
| Sample type | EDTA plasma, CSF, brain homogenate, Cell Culture Supernatant |
| LoB | ≤0.50 pg/mL |
| Linear range | 1.00–100.00 pg/mL |
| Linear correlation coefficient | r ≥0.9900 |
| Repeatability (CV) | ≤8.00% |
| Intermediate precision (CV) | ≤15.00% |
| Trueness | −15% to +15% |
| Calibrators | 3 levels |
| Quality control | 2 levels |
| Compatible analyzer | Elf S290R |
| Sample Volume | 50μL |
| Storage | 2–8 °C, protected from light |
| Shelf life | 12 months |
| Intended use | Research Use Only (RUO) |
Reasearch Application
Quantitative Aβ1-42 measurement in research samples for Alzheimer’s disease biomarker research.
Aβ1-42 / Aβ1-40 ratio studies to support amyloid pathology characterization.
Multi-biomarker panels together with Aβ1-40, p-Tau 217, p-Tau 181, GFAP, and NfL.
Longitudinal and cohort monitoring of Aβ1-42 dynamics in research cohorts.
Assay Principle
The assay uses a double-antibody sandwich format. Magnetic particles coated with capture antibody bind Aβ1-42 from the sample; an acridinium ester-labeled detection antibody produces a chemiluminescent signal (RLU) proportional to the Aβ1-42 concentration.
Magnetic-particle capture: capture antibodies on magnetic particles bind Aβ1-42 from the sample.
Wash: unbound material is removed before detection.
Acridinium-ester detection antibody: the labeled antibody completes the sandwich complex.
RLU signal: the chemiluminescent signal is proportional to the Aβ1-42 concentration.
Kit Contents and Compatibility
Compatible instruments
Automatic Chemiluminescence Immunoassay Analyzer, Model Elf S290R
Kit contents
Our ready-to-use β-Amyloid 1-42 (Aβ1-42) (CLIA) kits contain all the reagents necessary to run your Aβ1-42 assays. Each kit contains enough reagents for 100 tests.
| Component | Quantity (per 100-test kit) |
|---|---|
| Magnetic Particle Suspension | 5.0 mL |
| Labeled Antibody Working Solution | 11.0 mL |
| Assay Diluent | 6.0 mL |
| Quality Control Materials | 1 set |
| Calibrators | 1 set |